Wave Life Sciences Ltd. 1U5.F Stock
Wave Life Sciences Ltd. Price Chart
Wave Life Sciences Ltd. 1U5.F Financial and Trading Overview
Wave Life Sciences Ltd. stock price | 5.4 EUR |
Previous Close | 3.62 EUR |
Open | 3.46 EUR |
Bid | 3.46 EUR x 0 |
Ask | 3.7 EUR x 0 |
Day's Range | 3.46 - 3.46 EUR |
52 Week Range | 1.76 - 6.39 EUR |
Volume | 10 EUR |
Avg. Volume | 0 EUR |
Market Cap | 340.37M EUR |
Beta (5Y Monthly) | -0.912323 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.47 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.86 EUR |
1U5.F Valuation Measures
Enterprise Value | 193.03M EUR |
Trailing P/E | N/A |
Forward P/E | -1.5656109 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 22.954329 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 13.018 |
Enterprise Value/EBITDA | -1.299 |
Trading Information
Wave Life Sciences Ltd. Stock Price History
Beta (5Y Monthly) | -0.912323 |
52-Week Change | 121.77% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.39 EUR |
52 Week Low | 1.76 EUR |
50-Day Moving Average | 3.65 EUR |
200-Day Moving Average | 4.02 EUR |
1U5.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 98.37M |
Float | 42.16M |
Short Ratio | N/A |
% Held by Insiders | 25.15% |
% Held by Institutions | 70.21% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1044.71% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -44.55% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 14.83M EUR |
Revenue Per Share (ttm) | 0.17 EUR |
Quarterly Revenue Growth (yoy) | 638.79% |
Gross Profit (ttm) | N/A |
EBITDA | -148634000 EUR |
Net Income Avi to Common (ttm) | -151414000 EUR |
Diluted EPS (ttm) | -1.61 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 207.56M EUR |
Total Cash Per Share (mrq) | 2.11 EUR |
Total Debt (mrq) | 36.61M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.656 |
Book Value Per Share (mrq) | -0.354 |
Cash Flow Statement
Operating Cash Flow (ttm) | -2386000 EUR |
Levered Free Cash Flow (ttm) | 1.31M EUR |
Profile of Wave Life Sciences Ltd.
Country | Germany |
State | N/A |
City | Singapore |
Address | Marina One East Tower |
ZIP | 018936 |
Phone | 65 6236 3388 |
Website | https://www.wavelifesciences.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 250 |
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.
Q&A For Wave Life Sciences Ltd. Stock
What is a current 1U5.F stock price?
Wave Life Sciences Ltd. 1U5.F stock price today per share is 5.4 EUR.
How to purchase Wave Life Sciences Ltd. stock?
You can buy 1U5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Wave Life Sciences Ltd.?
The stock symbol or ticker of Wave Life Sciences Ltd. is 1U5.F.
Which industry does the Wave Life Sciences Ltd. company belong to?
The Wave Life Sciences Ltd. industry is Biotechnology.
How many shares does Wave Life Sciences Ltd. have in circulation?
The max supply of Wave Life Sciences Ltd. shares is 124.88M.
What is Wave Life Sciences Ltd. Price to Earnings Ratio (PE Ratio)?
Wave Life Sciences Ltd. PE Ratio is now.
What was Wave Life Sciences Ltd. earnings per share over the trailing 12 months (TTM)?
Wave Life Sciences Ltd. EPS is -0.47 EUR over the trailing 12 months.
Which sector does the Wave Life Sciences Ltd. company belong to?
The Wave Life Sciences Ltd. sector is Healthcare.